References
- Dreyling M, Hiddemann W: Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book Hematology 2009: 542–554.
- Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010 Feb 15;70(4):1408–18.
- Harris NH, Jaffe ES, Diebold, J et al. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. JCO December 1, 1999 vol. 17 no. 12 3835–38.
- Lennert K, Mohri N, Stein H, Kaiserling E. The Histopathology of Malignant Lymphoma. Br J Hematol. 1975;31(s1); 193–203.
- Galton DA, Szur L, Dacie JV. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Br J Hematol; 1961;7;73–98.
- Knospe WH, Virgil L, Huguley CM. Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer. 1974;33:555–562
- Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326–1331
- Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174.
- Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009 Oct 15;114:3382–91.
- Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Hematol. 2003;123:271–277
- Sanchanas S, Pangalis GA, Vassilakopoulos TP, et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leukemia Lymp :2011;52:387–393
- Olivier Hermine, Eva Hoster, Jan Walewski, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood, Volume 116 ;21; #110.
- Martin P, Chadburn A, Christos P, et al. outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209–1213.
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL ASH 2009, #405.